Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Accumulated Expenses (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Accumulated Expenses for 6 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 56.68% to $13.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Dec 2025, down 56.68% year-over-year, with the annual reading at $13.2 million for FY2025, 56.68% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $13.2 million at Lexicon Pharmaceuticals, down from $13.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $30.4 million in Q4 2024, with the low at $10.1 million in Q1 2023.
  • Average Accumulated Expenses over 3 years is $16.5 million, with a median of $15.5 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses soared 77.46% in 2024, then plummeted 56.68% in 2025.
  • Over 3 years, Accumulated Expenses stood at $17.2 million in 2023, then skyrocketed by 77.46% to $30.4 million in 2024, then tumbled by 56.68% to $13.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $13.2 million, $13.6 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.